Opinion|Videos|August 20, 2024

Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

Author(s)Trinity Bivalacqua, MD, PhD, Mark D. Tyson, MD, MPH

Experts discuss the results of the CORE-001 Trial.

Episodes in this series

EP. 1 Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP. 1 Prevalence and Staging of Newly Diagnosed Bladder Cancer

EP. 2 Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

EP. 2 Impact of BCG Therapy Shortage on the Management of High-Risk NMIBC

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 3 Recurrence and BCG Resistance in High-Risk NMIBC

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 4 Therapies Beyond BCG: FDA-Approved and Emerging Options

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 5 Cretostimogene, Grenadenorepvec, and Pembrolizumab for BCG-Unresponsive NMIBC: Overview of ASCO 2024 Data

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 6 CORE-001 Trial Participation and Eligibility Criteria

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 7 Comparing Cretostimogene and BCG Administration Methods

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 8 Results of the CORE-001 Trial: 24-Month Complete Response Rate and Duration of Response

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 9 Safety Outcomes and Duration of Response in Combination Therapy vs. Monotherapy for BCG UR CIS +/- Papillary Disease

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 10 Evaluating the Benefits of Cretostimogene Plus Pembrolizumab for BCG-Unresponsive NMIBC Management

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 11 Evaluating Cretostimogene: BOND-003 and PIVOT-006 Trial Results

Trinity Bivalacqua, MD, PhD, and Mark Tyson, MD, MPH, experts on bladder cancer

EP. 12 Managing BCG-Unresponsive NMIBC: Cretostimogene Monotherapy vs. Combination Therapy

Video content above is prompted by the following questions:

In the CORE-001 trial, what were the results for the primary endpoint of complete response at 24 months as well as the secondary endpoint of duration of response? What is notable about these results?
How do these results compare to those associated with other FDA-approved therapies and other investigational drugs?
What was the overall cystectomy-free survival rate, and what was this rate among patients who experienced a complete response?
Were there other notable efficacy outcomes?

Newsletter

Stay current with the latest urology news and practice-changing insights — sign up now for the essential updates every urologist needs.

Related to this article

Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC

October 16th, 2026

Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC

Long-term QUILT-3.032 findings show durable responses with Anktiva plus BCG in BCG-unresponsive NMIBC, with an estimated 84.2% cystectomy-free survival at 3 years.

The UroOnc Minute: Managing Intravesical Therapy Toxicity in NMIBC, With Vignesh Packiam, MD

October 16th, 2026

The UroOnc Minute: Managing Intravesical Therapy Toxicity in NMIBC, With Vignesh Packiam, MD

Vignesh Packiam, MD, discusses strategies to manage intravesical therapy toxicity in NMIBC, improve treatment tolerability, and preserve bladder function.

October 16th, 2026

Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution

Sandip M. Prasad, MD, MPhil, discusses the safety profile of mitomycin intravesical solution, including common adverse events and patient counseling during chemoablation for NMIBC.

Three-year data show durable responses with mitomycin intravesical solution

October 15th, 2026

Three-year data show durable responses with mitomycin intravesical solution

Sandip M. Prasad, MD, MPhil, discusses 3-year ENVISION trial data showing durable responses with mitomycin intravesical solution for recurrent LG-IR-NMIBC.

Armine K. Smith, MD, on sexual health counseling before cystectomy

October 15th, 2026

Armine K. Smith, MD, on sexual health counseling before cystectomy

Armine K. Smith, MD, discusses sexual health counseling, sex-specific considerations, and organ-preserving approaches for patients undergoing radical cystectomy.

FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC

October 14th, 2026

FDA approves nogapendekin alfa inbakicept plus BCG for papillary-only BCG-unresponsive NMIBC

This approval expands the label for nogapendekin alfa inbakicept to include patients with high-grade papillary-only tumors.

Timothy Clinton, MD, reviews bladder cancer data from 2026 AUA Northeastern Section Meeting

October 13th, 2026

Timothy Clinton, MD, reviews bladder cancer data from 2026 AUA Northeastern Section Meeting

Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.

ENVISION data inform the use of chemoablation in recurrent LG-IR-NMIBC

October 12th, 2026

ENVISION data inform the use of chemoablation in recurrent LG-IR-NMIBC

Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.

Trending on Urology Times

Anktiva plus BCG shows durable responses in BCG-unresponsive NMIBC

Sandip Prasad, MD, on the safety profile of mitomycin intravesical solution

Three-year data show durable responses with mitomycin intravesical solution

Urocross Expander System enters US commercial use for symptomatic BPH

FAQs: The AUA 2025 Guideline on Genitourinary Syndrome of Menopause